ABOUT US

Travere Therapeutics is a biopharmaceutical company whose mission is to identify, develop and deliver life-changing therapies to people living with rare disease.

We stick by our values

We are patient-inspired.
We are courageous.
We promote community.
We are stronger together.

And we pursue our vision of becoming a leading biopharmaceutical company dedicated to the delivery of innovation and hope to patients in the global rare disease community.

Our Culture

We are impatient for the patients we serve.

We are driven to deliver safe and effective therapies to patients as quickly as possible. To do this, we are advancing a pipeline of potential first-in-class medicines targeting rare diseases with significant unmet needs and oftentimes no approved treatment options.

Our efforts are led by late-stage development programs of sparsentan, which is a novel product candidate targeting rare kidney diseases – focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN).

We are also partnering with leaders in patient advocacy and the National Institutes of Health (NIH) on earlier-stage development work in rare liver diseases. In addition, pegtibatinase (TVT-058), the first potential disease-modifying therapy for the treatment of classical homocystinuria (HCU), is in Phase 1/2 development.

Today we aim to help patients with our four approved commercial therapies, Chenodal® (chenodiol), Cholbam® (cholic acid), Thiola® (tiopronin), and Thiola EC® (tiopronin) delayed-release tablets. We are committed to broad access for our FDA-approved therapies, and we provide personalized clinical support services through the Total Care Hub. We also sponsor diagnostic testing at no cost to qualified patients to help accurately diagnose a variety of disorders.

Nonstop focus on people living with rare disease

Because of our patient-centered purpose and recognition that rare disease has no borders, we supported the creation of the Rare Disease Network at Children’s National Rare Disease Institute (CNRDI). The network exists to improve rare disease care in the US and internationally through innovative digital medicine technology and partnerships with rare disease experts.

In our commitment to support caregivers of people living with rare disease, we worked with NORD to establish the Rare Caregiver Respite Program, and with the National Alliance of Caregivers to better understand and help meet the needs of rare caregivers.

We also supported the first-ever Diversity Inclusion Advocacy Fellowship at the EveryLife Foundation for Rare Diseases to increase the representative diversity of patient voices and to engage low income and minority communities in advocacy.

Through our portfolio of approved products and our promising pipeline, we strive to help people achieve the best possible outcomes today and tomorrow.

Senior Leadership Board of Directors Culture Careers Contact Us

Pathfinder

Travere Therapeutics Provides Regulatory Updates on its Development Programs

News

SAN DIEGO, Aug. 03, 2022 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today provided regulatory updates for its sparsentan programs in IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS), as well as its pegtibatinase program for classical homocystinuria (HCU).

Read the full press release >

Eric Dube Named EY Entrepreneur of the Year 2022 Pacific Southwest Award Winner

News

Ernst & Young today announced that our CEO Eric Dube has been named an Entrepreneur of the Year 2022 Pacific Southwest Award winner! This prestigious award recognizes exemplary leaders who lift up their employees and their communities and are focused on creating a better world for all. A panel of independent judges selected 13 winners out of the 40 finalists who were eligible for the award.

Travere Therapeutics Announces Presentations of Abstracts at the 59th ERA Congress

News

SAN DIEGO, May 17, 2022 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced presentations including baseline characteristics for patients enrolled in the ongoing pivotal Phase 3 PROTECT and DUPLEX studies of sparsentan in IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS), respectively, at the 59th European Renal Association (ERA) Congress. The Company and its collaborators will also present nonclinical data examining the renal protective effects of sparsentan compared to controls. ERA is being held live in Paris, France, and virtually May 19-22, 2022.

Read the full press release >

Travere Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Sparsentan for the Treatment of IgA Nephropathy

News

SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review of its New Drug Application (NDA) under Subpart H for accelerated approval of sparsentan for the treatment of IgA nephropathy (IgAN).

Read the full press release >

Stephanie

IgAN, Rare Life

In the spring of 2020, after a hike with her husband and kids, Stephanie’s legs swelled unfathomably. She took a video of herself pressing her fingers into her legs, showing how her fingers would sink into the skin.

Travere Therapeutics Reports First Quarter 2022 Financial Results

News

SAN DIEGO, May 5, 2022 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today reported its first quarter 2022 financial results and provided a corporate update.

Read the full press release >

ABOUT US

We stick by our values

We are patient-inspired. We are courageous. We promote community. We are stronger together.

We are impatient for the patients we serve.

Nonstop focus on people living with rare disease

Through our portfolio of approved products and our promising pipeline, we strive to help people achieve the best possible outcomes today and tomorrow.

Pathfinder

We are patient-inspired.
We are courageous.
We promote community.
We are stronger together.